CIK 0001674416 · Large accelerated filer
CRISPR Therapeutics AG
Sign in to watch- Ticker
- CRSP
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- Switzerland
- Entity type
- operating
- EIN
- 473173478
- Phone
- 6173154600
- Business address
- BAARERSTRASSE 14, ZUG, Switzerland
- Former names
- CRISPR Therapeutics AG
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $4,881,673
- in 7 filings, $1.5M under 10b5-1 plans
Net −$4,881,673. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-02-18 | KASINGER JAMES R. General Counsel and Secretary | Sale | −9,595 | $53.85 | $517K | 73,002 |
| 2025-02-18 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | +3,825 | 76,827 | ||
| 2025-02-18 | KASINGER JAMES R. General Counsel and Secretary | Option exercise · Restricted Stock Units | −3,825 | 3,825 | ||
| 2025-02-18 | Kulkarni Samarth Chief Executive Officer | Option exercise 10b5-1 | +13,250 | 208,541 | ||
| 2025-02-18 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −11,640 | $55.05 | $641K | 196,901 |
| 2025-02-18 | Kulkarni Samarth Chief Executive Officer | Option exercise · Restricted Stock Units 10b5-1 | −13,250 | 13,250 | ||
| 2025-02-16 | KASINGER JAMES R. General Counsel and Secretary | Option exercise | +20,000 | 82,597 | ||
| 2025-02-16 | KASINGER JAMES R. General Counsel and Secretary | Option exercise · Restricted Stock Units | −20,000 | 0 | ||
| 2024-12-24 | Kulkarni Samarth Chief Executive Officer | Option exercise | +13,751 | $16.21 | $223K | 195,291 |
| 2024-12-24 | Kulkarni Samarth Chief Executive Officer | Option exercise · Stock Option (Right to Buy) | −13,751 | 0 | ||
| 2024-12-02 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −15,000 | $55.10 | $827K | 181,540 |
| 2024-11-11 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −23,121 | $55.43 | $1.3M | 203,419 |
| 2024-11-11 | Kulkarni Samarth Chief Executive Officer | Sale 10b5-1 | −6,879 | $56.27 | $387K | 196,540 |
| 2024-10-16 | Patel Naimish Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +18,333 | 18,333 | ||
| 2024-10-16 | KASINGER JAMES R. General Counsel and Secretary | Grant or award · Stock Option (Right to Buy) | +18,333 | 18,333 | ||
| 2024-10-16 | KASINGER JAMES R. General Counsel and Secretary | Grant or award · Restricted Stock Units | +30,000 | 30,000 | ||
| 2024-10-16 | Bruno Julianne Chief Operating Officer | Grant or award · Stock Option (Right to Buy) | +18,333 | 18,333 | ||
| 2024-10-16 | Kulkarni Samarth Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +55,000 | 55,000 | ||
| 2024-10-16 | Kulkarni Samarth Chief Executive Officer | Grant or award · Restricted Stock Units | +400,000 | 400,000 | ||
| 2024-10-16 | Prasad Raju Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +18,333 | 18,333 |
Page 11 of 46 · 910 trades